

Cancer Cell

Volume 22
Number 3

September 11, 2012

www.cellpress.com



**Dual Role of Par3
in Skin Carcinogenesis**

Transforming the Microenvironment: A Trick of the Metastatic Cancer Cell

Anuradha Budhu¹ and Xin Wei Wang^{1,*}

¹Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, 37 Convent Drive, Bethesda, MD 20892, USA

*Correspondence: xw3u@nih.gov

<http://dx.doi.org/10.1016/j.ccr.2012.08.018>

Creating a permissive microenvironment is a strategy employed by tumor cells to disseminate. In this issue of *Cancer Cell*, Yang et al. identify the molecular signaling events that connect hepatitis infection with TGF β activity and T regulatory cell recruitment to establish a favorable microenvironment for tumor metastasis.

Metastasis is a significant contributor to morbidity and mortality among cancer patients. Such patients are often considered incurable, with treatments offering either supportive care or aggressive management without curative intent. For over a century, cancer biologists have intensely explored the mechanisms underlying the emergence and spread of tumor cells (Valastyan and Weinberg, 2011). Although much progress has been made in elucidating signaling networks of metastasis, the sheer complexity of this dynamic and intricate process has thwarted our ability to define effective targets for cancer management.

An interesting form of metastases is observed in hepatocellular carcinoma (HCC) with a unique dissemination pattern within the liver, a significant proportion of which colonize inside the major branches of the portal vein, a condition called portal vein tumor thrombosis (PVTT). PVTT can lead to further liver deterioration along with ascites and esophageal bleeding, thus presenting a major treatment challenge. A few studies have explored the role of genomic alterations in PVTT and have identified critical players, such as osteopontin, in HCC metastasis (Ye et al., 2003). Profiling of the liver microenvironment of metastasis patients has shown that global shifts in inflammatory cytokines can provide a suitable niche to promote disease progression (Budhu et al., 2006). A more detailed understanding of the complex interplay of signals between tumors and the organs they invade is paramount to improving cancer patient care and in developing clinical strategies to block cancer progression.

One player at the forefront of metastasis is TGF β . This multifunctional cyto-

kine signals through a complex network of transduction pathways during embryonic development, cell proliferation, differentiation, angiogenesis, and wound healing. It can function as a tumor suppressor in premalignant cells by inducing apoptosis, cell cycle arrest, and immune surveillance while suppressing cytokines, chemokines, and inflammation (Ikushima and Miyazono, 2010). Its expression in many cell types allows it to orchestrate this vast set of processes. TGF β signals through a canonical pathway via TGF β receptors and its downstream Smad mediators to recruit a network of factors in a cell-specific and context-dependent manner to regulate target genes. The suppressive effects of TGF β can be circumvented by malignant cells through inactivation of these components, such as mutations in TGFBR2 and SMAD4. TGF β can also signal in a noncanonical fashion via PI3K, MAPK, and small GTP pathways. Under these circumstances, cancer cells can alter and seize TGF β 's downstream tumor suppressive signaling components to promote tumor progression. This Jekyll and Hyde nature of TGF β can drive cancer spread via cell autonomous or nonautonomous mechanisms by impacting the host cell.

Inflammation and the tumor microenvironment play significant roles in tumor progression and are identified as hallmarks of cancer (Hanahan and Weinberg, 2011). A complex milieu of cells are at the ready in the premalignant state to fend off infection and disease, but can be usurped by tumor cells for more insidious roles such as metastatic initiation and progression. TGF β , an immune and inflammation regulator, is frequently present in the microenvironment as a signal to prevent premalignant progression; however,

malignant cells with high TGF β may be shielded from immune surveillance, while defective TGF β signaling can lead to chronic inflammation and the production of a pro-tumorigenic environment. Although several studies have described a dual role for TGF β in cancer, the mechanisms underlying these roles and how they can be exploited for clinical relevance remains obscure. What causes altered TGF β signaling in cancer? When does TGF β act as a metastasis signal? How does TGF β alter the tumor microenvironment? How can we use this knowledge to treat cancer?

In this issue of *Cancer Cell*, Yang et al. (2012) report that TGF β promotes a metastasis-permissive microenvironment in the portal vein of hepatitis B virus (HBV)-positive liver cancer patients. This switch toward a progressive phenotype occurs through the recruitment of immune suppressive CD4⁺CD25⁺ T regulatory (Tregs) cells mediated by TGF β suppression of microRNA-34a (miR-34a) and the consequent release of CCL22 activity (Figure 1). Among 288 Chinese HCC patients, Yang et al. (2012) found a strong correlation between HBV status and the presence of PVTT, concomitant with elevated TGF β activity. In a screen of microRNAs related to metastasis, they found that reduced levels of miR-34a, a tumor suppressor previously identified in a HCC metastasis signature (Budhu et al., 2008), was associated with HBV⁺ HCC and high TGF β levels. Moreover, a quantitative assay showed that the chemokine CCL22 is a bona fide target of miR-34a. Using in vitro assays and mouse models of liver or lung metastasis, they demonstrate that TGF β signaling, via miR-34a suppression and consequent elevation of CCL22, enhances

recruitment of Tregs to create an immune suppressive microenvironment, thereby promoting metastasis.

These results raise several interesting questions and opportunities for further exploration of TGF β signaling and its relation to cancer and metastasis. While the patients studied by Yang et al. (2012) largely consist of HBV⁺ patients, several other underlying etiologies play a significant role in liver cancer development. The most prominent of these are hepatitis C virus (HCV) infection, alcoholic liver disease, and obesity, all of which are major global health burdens in both developing and developed countries. In the context of viral infection, HBV and HCV

promote liver cancer and progression in disparate ways. It would be of interest to determine whether TGF β can be modulated by HCV to similarly affect miR-34a and CCL22 or different signals are activated dependent on the risk factor present for HCC.

Yang et al. (2012) have elegantly demonstrated the connection between HBV infection and the activation of Treg recruitment to promote metastasis. In future studies, it will be intriguing to decipher how HBV affects TGF β level. Is this due to integration of the HBV-encoded HBx gene or some other mechanism? The role of TGF β in HBV patients without PVT will be useful in determining what drives and regulates the molecular switch to promote metastasis. It would also be of interest to determine how TGF β suppresses miR-34a. Recent studies have shown that p53 mutation is involved in




Figure 1. Cell Autonomous and Nonautonomous Activities of the TGF β Signaling Network in Tumor and Stromal Cells

A potential therapeutic opportunity for the treatment of liver cancer metastasis is outlined. In metastatic HCC cells, TGF β induction can be triggered by HBV infection, which then suppresses miR-34a, a suppressor of CCL22, resulting in the induction and secretion of CCL22. This chemokine, in turn, recruits Tregs to create an immune tolerant microenvironment that promotes metastatic colonization. The balancing activities of TGF β and immune cells resemble the principle represented by the Yin-Yang symbol. Therefore, CCL22 represents a potential druggable target for metastatic HCC. The solid lines represent a direct action, and dotted lines represent a link with an unsolved mechanism.

switching TGF β from a tumor suppressor to a tumor promoter (Adorno et al., 2009) and miR-34a has been shown to be a direct target of p53 (He et al., 2007). The role of p53 in TGF β -mediated HBV⁺ HCC metastasis will be interesting to explore since p53 mutation occurs in certain HCC populations, while HBx can bind and inactivate p53-dependent processes.

TGF β targeting is quite complex, and a clinically useful drug has not been successfully produced. Strategies have included reducing the ligand by siRNA, blocking ligand-receptor interactions by monoclonal antibodies, or inhibiting signaling by small molecule inhibitors (Calone and Souchelnytskyi, 2012). Yang et al.'s study has highlighted an important molecule in TGF β -mediated metastasis, namely CCL22. This study therefore opens up an avenue to explore this

secreted chemokine as a target for effective treatment of HCC metastasis. Metastasis remains the major cause of death among cancer patients. Here, Yang et al. (2012) have revealed an important signaling layer of TGF β , which sheds light on its role in promotion of metastasis and leads to a promising therapeutic target to clinically manage aggressive cancer.

REFERENCES

- Adorno, M., Cordenonsi, M., Montagner, M., Dupont, S., Wong, C., Hann, B., Solari, A., Bobisse, S., Rondina, M.B., Guzzardo, V., et al. (2009). *Cell* 137, 87–98.
- Budhu, A., Forgues, M., Ye, Q.H., Jia, H.L., He, P., Zanetti, K.A., Kamula, U.S., Chen, Y., Qin, L.X., Tang, Z.Y., and Wang, X.W. (2006). *Cancer Cell* 10, 99–111.
- Budhu, A., Jia, H.L., Forgues, M., Liu, C.G., Goldstein, D., Lam, A., Zanetti, K.A., Ye, Q.H., Qin, L.X., Croce, C.M., et al. (2008). *Hepatology* 47, 897–907.
- Calone, I., and Souchelnytskyi, S. (2012). *Exp. Oncol.* 34, 9–16.
- Hanahan, D., and Weinberg, R.A. (2011). *Cell* 144, 646–674.
- He, L., He, X., Lim, L.P., de Stanchina, E., Xuan, Z., Liang, Y., Xue, W., Zender, L., Magnus, J., Ridzon, D., et al. (2007). *Nature* 447, 1130–1134.
- Ikushima, H., and Miyazono, K. (2010). *Nat. Rev. Cancer* 10, 415–424.
- Valastyan, S., and Weinberg, R.A. (2011). *Cell* 147, 275–292.
- Yang, P., Li, Q.-J., Feng, Y., Zhang, Y., Markowitz, G.J., Ning, S., Deng, Y., Zhao, J., Jiang, S., Yuan, Y., et al. (2012). *Cancer Cell* 22, this issue, 291–303.
- Ye, Q.H., Qin, L.X., Forgues, M., He, P., Kim, J.W., Peng, A.C., Simon, R., Li, Y., Robles, A.I., Chen, Y., et al. (2003). *Nat. Med.* 9, 416–423.